Public health

Diffuse large B-cell lymphoma
#Epidemiology #GlobalData #Hodgkin lymphoma #Public health

Classical Hodgkin lymphoma cases projected to reach 28,000 by 2035

The number of newly diagnosed classical Hodgkin lymphoma cases across the US, France, Germany, Italy, Spain, the UK, Japan and China (8MM) is expected to rise from 27,000 in 2025 to 28,000 by 2035, according to GlobalData. The company’s latest report, Hodgkin Lymphoma: Epidemiology Report and Forecast, projects an annual… Read More

#News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug development #ICON #Public health

ICON on the real-world integration of AI in drug R&D

DDW’s Megan Thomas speaks with ICON's IT Director, Marco Heldoorn, about leveraging artificial intelligence (AI) to enhance efficiency, decision-making, and patient outcomes across the drug development lifecycle, from early feasibility to post-marketing. MT: Could you provide an overview of your findings when it comes to drug development and AI? TO:… Read More

#Business & Investment #Exclusive Content

#Astex Pharmaceuticals #Bioorthogonal chemistry #Click chemistry #Cognitive impairment #Covid-19 #Drug discovery #Life sciences #Long Covid #Molecular Biology #Neuroscience #Public health

Podcast: Innovative approaches to improving drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative approaches to improving drug discovery”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: Post-Covid cognitive impairment: a new target for drug development?, Sitting Down… Read More

#News

#Collaboration #Genomics #Genomics England #NHS #Public health #Research #Revvity

Collaboration to advance UK genomics research 

Revvity has announced an expansion of its working relationship with Genomics England that leverages both organisations' expertise and resources to advance critical genomic initiatives across the United Kingdom.   Building on the parties’ long and productive work history, this collaboration is dedicated to accelerating Genomics England’s research programmes, supporting diverse areas… Read More

#Business & Investment #News

#Biobanking #Genome sequencing #Genomics #PacBio #Public health #Whole genome sequencing

Estonia National Biobank to sequence 10,000 whole genomes 

PacBio has announced that the University of Tartu, host of Estonia’s National Biobank, has chosen the company’s Revio HiFi sequencing system to sequence 10,000 whole human genomes and unlock new insights from its population health data.    The announcement follows funding from the European Commission and… Read More

#News

Pain killers
#Drug development #Ensysce Biosciences #Opioids #Painkillers #Public health

In Conversation With: Dr Lynn Kirkpatrick, Ensysce Biosciences

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dr Lynn Kirkpatrick, CEO… Read More

#News

Scientific technology
#AI / data analytics / healthtech / informatics #Clinical development #Data automation #Data management #Diagnostics #Drug discovery #Electronic Lab Notebooks (ELN) #FAIR Principles #Genomics #Immunology / Virology & Vaccines #Infectious diseases #Informatics #mRNA #Personalised medicine #Precision medicine #Predictive diagnostics #Public health

New podcast: Revolutionary technology for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: mRNA technology may hold the future for a cytomegalovirus vaccine; … Read More

#News

#Astex Pharmaceuticals #Covid-19 #Drug discovery #Life sciences #Public health

Sitting down with… Dr Harren Jhoti, Astex Pharmaceuticals

Listen to this article on the DDW Podcast: Following his recent OBE, Diana Spencer speaks to Dr Harren Jhoti about his career, the UK life sciences sector, fragment-based drug discovery and what the future holds for the industry. At the end of 2022, Astex Pharmaceuticals co-founder, President and CEO Dr Harren… Read More

#Cancer Research #Exclusive Content

#AstraZeneca #Biobanking #Covid-19 #Genetics #Genomics #Public health #Research

Podcast: Is genomic data the new frontier in drug discovery?

This is the latest episode of the free narrated DDW podcast, “Is genomic data the new frontier in drug discovery?” It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “Genomics boosts understanding of Covid-19 severity and susceptibility” and “… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19 #Drug development #Healthcare #Public health #Regulatory

Drug development practices to improve public health policy 

Dr Andrew Garrett, Executive Vice President of Scientific Operations at ICON, explores the benefits of integrating some of the validation and standardisation practices already developed for PIs into the practices around NPIs and public health data; outlines some of the practices that can be implemented in order to do this;… Read More

#Exclusive Content #Opinion #Regulatory

#Drug discovery #Genetic study #Health research programme #Healthcare #NHS #Predictive diagnostics #Public health

How Our Future Health will impact drug discovery 

Recently, DDW reported on how over three million people have been invited to join Our Future Health. Andrew Roddam, CEO of Our Future Health, shares the impact research programmes such as this will have on drug discovery.  Millions of people in the UK and around the world spend many years… Read More

#Exclusive Content #Opinion

#Data #Diagnostics #Genetics / genomics #Healthcare #Public health #Rare disease #Whole genome sequencing

Personalising WGS doubles diagnosis of rare diseases 

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases.  Context   In 2018, the UK’s department of health announced an NHS Genomic Medicine… Read More

#News

Genomics
#Biotechnology #Comment #Data #Gene editing #Genetics / genomics #Genome sequencing #Healthcare #Public health #Research #Whole genome sequencing

Why genomic healthcare data matters in the development of new therapies 

Genomic healthcare data is critical to identify disease risk, ancestry, traits and response to medicines and aids in the development of new targeted therapies - precision medicines. DDW’s Megan Thomas observes developments of accessibility in this sector and the potential impact.  The origins  One might argue that this all started… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Cancer research #Genetics / genomics #Public health

Qatar Genome Programme data improves cancer screening 

A study by the Qatar Genome Research Consortium, led by Dr Lotfi Chouchane from Weill Cornell Medicine-Qatar, has reported the first landscape of cancer germline mutations – hereditary mutations – in the Qatari population.  Since then, scientists at Qatar Foundation’s (QF) Qatar Genome Programme (QGP) have teamed… Read More

#News

#Clinical development #Immunology / Virology & Vaccines #Infectious diseases #mRNA #Public health

mRNA technology may hold the future for a cytomegalovirus vaccine 

Listen to this article on the DDW podcast: Allison August, M.D., Vice President, Clinical Development, Infectious Diseases at Moderna examines the data on cytomegalovirus (CMV), why attempts at vaccines for CMV have so far proved elusive and the emerging options to address this unmet need.  Although cytomegalovirus (CMV) is almost… Read More

#Exclusive Content #Trends & Analysis

#Clinical trials #Drug development #Opinion #Patient centricity #Public health

What can patients do to give input into clinical trial design? 

Business and profitability remain unquestionably important in the drug discovery community. However, the industry’s overarching goal of public health and the betterment of society have never been more apparent than in the aftermath of the pandemic and when observing the heights scientists reached through determination and collaboration in the fight… Read More

#Exclusive Content #Opinion